Pomerantz LLP Advises Shareholders of Class Action Filing Involving Cytokinetics, Incorporate – CYTK

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ:CYTK).â?¯â?¯ Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged […]

Pomerantz LLP Alerts Shareholders to Investor Suit Filed Against Marex Group Plc – MRX

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Marex Group Plc ("Marex" or the "Company") (NASDAQ:MRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

Pomerantz LLP Announces The Filing of a Class Action Lawsuit Against Fluor Corporation – FLR

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fluor Corporation ("Fluor" or the "Company") (NYSE:FLR) and certain officers.�� The class action, filed in the United States District Court for the Northern District of Texas, Dallas Division, and docketed under

Pomerantz LLP Calls Attention to Class Action Against Quanex Building Products Corporation – NX

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation ("Quanex" or the "Company") (NYSE:NX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail

BAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Baxter International, Inc. ("Baxter" or "the Company") (NYSE:BAX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

Pomerantz LLP Advises of Securities Class Action Involving Fortinet, Inc. – FTNT

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or the "Company") (NASDAQ:FTNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

SINA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sina Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / November 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sina Corporation ("Sina" or "the Company") (NASDAQ:SINA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for

SVRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Savara Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Savara Inc. ("Savara" or "the Company") (NASDAQ:SVRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients Platinum sponsorship of NF Caregivers Symposium reinforces commitment to NF1 community GlobeNewswire November 04, 2025 MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the

LNTH INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Lantheus Holdings, Inc. to Contact the Firm Today!

NEW YORK, NY / ACCESS Newswire / November 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ:LNTH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

Scroll to Top